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A high throughput screening method for the
nano-crystallization of salts of organic cations†
Philipp P. Nievergelt, ‡a Martin Babor, ‡ab Jan Cˇejka b
and Bernhard Spingler *a
The generation of solid salts of organicmolecules is important to the chemical and pharmaceutical industry.
Commonly used salt screening methods consume a lot of resources. We employed a combination of ion
exchange screening and vapour diﬀusion for crystallization. This technique is semi-automatic and
requires just nanoliters of the solution of the analyte to be crystallized. This high throughput screening
yielded single crystals of suﬃcient size and quality for single-crystal X-ray structure determination using
an in-house X-ray diﬀractometer. The broad scope of our method has been shown by challenging it
with 7 very diﬀerent organic cations, whose aqueous solubilities vary by a factor of almost 1000. At least
one crystal structure for 6 out of 7 tested cations was determined; 4 out of the successful 6 ones had
never been crystallized before. Our method is extremely attractive for high throughput salt screening,
especially for active pharmaceutical ingredients (APIs), as about 40% of all APIs are cationic salts.
Additionally, our screening is a new and very promising procedure for the crystallization of salts of
organic cations.
Introduction
Organic salts are multi-component ionic compounds, in which
at least one of the components is an organic ion. The focus of
this paper is the organic, cationic part of salts. Diﬀerent salts of
the same organic cation can have signicantly diﬀerent physi-
cochemical properties.1–6 The critical properties are solubility,7
crystal shape, hygroscopicity, melting point, and physical as
well as chemical stability. The selection of a suitable anion can
avoid problems during production, storage or shipping of an
organic salt. For example, an appropriate anion can improve the
purication and ow properties of the powder and/or reduce
the hygroscopicity. Therefore, salt screening is a decisive step
during the development and optimization of the production
process of an organic salt.2 It can signicantly reduce the
production cost of the chemical or pharmaceutical, as about
40% of all active pharmaceutical ingredients (APIs) are cationic
salts.8 However, there are also requirements for an ideal
screening. It shall require the least possible amount of material,
human work and time. At the same time, it should be as
eﬀective as possible in discovering new salts. Additionally, the
ability to analyse the new crystalline forms directly from the
basic screening would be a great advantage, ideally by single
crystal X-ray diﬀraction (SCXRD) structure analysis, since fast
access to SCXRD can save a lot of material and lab work, such as
immediately identifying false positive screening hits.
Recently, several innovations have been described that, with
the help of crystallography, allow the structure determination of
compounds, which had previously been impossible by applying
the methods of traditional crystal growth.9,10 The ‘crystalline
sponge’ method was originally introduced in 2013 by Fujita and
co-workers11 and has further been improved over the last few
years.12,13 This method opened up new possibilities for deter-
mining the crystal structures of apolar compounds that are
available only in minute amounts. However, this method is a 3
step procedure: (1) synthesis of the MOF host, (2) exchange of
the previous solvent by an apolar one, and (3) soaking of the
MOF crystal with the analyte. All steps are non-trivial to perform
and especially the last step has to be optimized for every single
compound. Alternative sponge methods have been described,
avoiding the exchange of guest molecules; however, they require
more analyte material and synchrotron radiation.14,15 Even the
most recent optimisation of the crystal sponge method is still
labour intensive, requires the analyte to be soluble in
dichloromethane and can only in exceptional cases be used as
an ab initio structure determination method without additional
knowledge of the analyte.16 A diﬀerent MOF lattice has recently
been developed by the group of Yaghi for the co-crystallization
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of carboxylates or alcohol containing molecules.17 Summarizing
the previous developments, a new method that could facilitate
the crystallization of cationic, polar compounds would be
highly desirable.
Results and discussion
Our new method addresses this need. Our screening technique
is based on two simple ideas and combines basic screening with
single crystal growth directly followed by structural analysis.
The rst hypothesis assumes that chloride salts of most cations
have the highest solubility in water and analogously that
sodium salts are the most common form of salts with a high
solubility in water. The second hypothesis supposes that a slow
increase of saturation might lead to the growth of single crys-
tals. According to the rst idea, if we mix solutions of organic
chloride salts with various sodium salts, the least soluble
combination of dissolved ions should crystallize, which should
be a new organic salt. In addition, the mixture of the starting
salts does not have to be equimolar, because all remaining ions
will still be dissolved in water. Concerning the second idea, an
increase of analyte concentration within a drop is generated by
the method of vapour diﬀusion (see ESI Fig. 1†), which was
previously developed for protein crystallization.18 This method
basically consists of mixing 100–500 nl of the analyte in water
with the same volume of a crystallization cocktail – in our case
this is normally a sodium salt – to generate a small drop of 200–
1000 nl volume. The drop is then equilibrated via the vapour
phase against the big reservoir consisting of only the crystalli-
zation cocktail. Since the crystallization cocktail in the drop was
diluted with the analyte, the water diﬀuses via the gas phase
back to the reservoir. The mixing of the analyte and the sodium
salt in the drop might already generate a supersaturated solu-
tion, while the diﬀusion of the water to the reservoir will
increase this eﬀect. In order to automate and miniaturize the
whole procedure, the pipetting of the reservoir and the drop
solutions, as well as the visual monitoring, is carried out by
a robot. Such robots are commonly being used in most
biochemical laboratories and pharmaceutical companies that
are engaged in structural biology projects.
Currently, the salt screening of active pharmaceutical
ingredients (APIs) that can be protonated is mainly done by
isolating and weighing the free base followed by addition of
diﬀerent acids in various solvents.19–21 This process is labour
intensive and can be unreliable, as some free bases are hygro-
scopic, prone to oxidation, or may otherwise be chemically
unstable. An additional disadvantage of this method is that the
ratio of API to acid has a direct inuence upon the pH in the
chosen solvent and therefore also upon the propensity to crys-
tallize. Furthermore, diﬀerent solvents might change the degree
of protonation of the API. Therefore, the amount of added acid
must be chosen carefully in advance for each solvent.
In order to evaluate our new method of crystallization, we
chose salts with seven quite diﬀerent organic cations (Fig. 1).
The chosen compounds include permanent cations (due to the
presence of tetraalkylated ammonium groups), as well as
Fig. 1 Selected compounds (5-benzyloxytryptaminium chloride, butyl scopolammonium bromide, (R,S)-carnitinenitrile chloride, (R)-()-car-
nitinenitrile chloride, iodide salt of the catalyst, (1S,2R)-(+)-ephedrine hydrochloride and trazodone hydrochloride) for crystallization and salt
screening.
Table 1 Needed amount of material in milligrams for one 96-well crystallization screening (assuming 100 nl consumption per crystallization
drop of a 90% saturated solution plus a 2 ml pipetting reserve for one 96-well plate)
[BaH]Cl [Bs]Br [(+/)-Car]Cl [()-Car]Cl [Cat]I [(+)-EphH]Cl [TrH]Cl
Amount [mg] 0.026 22 13 16 0.083 3.1 0.46
Aqueous solubility [mg ml1] 2.2  0.1 1800  200 1120  106 1300  200 6.9  0.1 257  1 38.5  0.2
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Table 2 Crystallization results
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compounds that can be protonated only at lower pH. Their
solubilities in water range from 2.2 to 1800 mg ml1 (Table 1).
Furthermore, we included a racemic compound to evaluate the
potential for enantiomeric resolution by chiral and sometimes
even enantiomerically pure anions. Additionally, we tested the
corresponding enantiomerically pure compound in order to
compare the ease of crystallization of a racemate and of one of
its enantiomers. Most of the chosen organic compounds have
no reported crystal structure at all, while one, ephedrine, is
known to form many diﬀerent salt forms.22 5-Benzyloxy-
tryptaminium chloride ([BaH]Cl) is an API, which acts as an
antagonist of the TRPM8 ion-channel. It is used for the treat-
ment of prostate cancer or benign prostate hyperplasia.23 The
Cambridge Structural Database (CSD)24 does not contain any
structure of 5-benzyloxytryptamine. Butyl scopolammonium
bromide ([Bs]Br) is being used to treat crampy abdominal pain,
renal colic, and esophageal and bladder spasms. The crystal
structure its methanol solvate has been reported.25 (R,S)-Carni-
tinenitrile chloride ([(+/)-Car]Cl) and (R)-()-carnitinenitrile
chloride ([()-Car]Cl) are being used as intermediates for the
preparation of carnitine or derivatives of carnitine, both of
which are APIs with many diﬀerent eﬀects from neurology to
diabetes mellitus.26–28 There is no structure of any
carnitinenitrile in the CSD. 2-(3-(3,5-Bis(triuoromethyl)
phenyl)-thioureido)-N,N,N-trimethylethanaminium iodide
([Cat]I) is the achiral version of chiral thiourea catalysts,29 and
the former can be used for the aminolysis of N-acyl homoserine
lactones.30 No structure of any salt that contains [Cat]+ can be
found in the CSD. (1S,2R)-(+)-Ephedrine hydrochloride
([(+)-EphH]Cl) is an active pharmaceutical ingredient used for
the treatment of emphysema and bronchial asthma. Many
crystal structures have been described for (+)-, ()- or
(+/)-ephedrine salts.22,31 Ephedrine was also used as a test case
for several salt screening studies.20,32 Trazodone hydrochloride
([TrH]Cl) is a selective inhibitor of serotonin and norepineph-
rine reuptake in a ratio of 25 : 1, and it is being used pharma-
ceutically as an antidepressant.33 Only the crystal structure of
trazodone hydrochloride has been reported and can be found in
the CSD.34
Our method employs a crystallization robot with a setup that
is commonly used in protein crystallography, but only excep-
tionally in small molecule crystallography.35 Initially, we chose
a crystallization setup that consisted of 500 nl of the aqueous
nearly saturated solution of the analyte; however repetitions of
the crystallizations with just 150 and 100 nl of the analyte solu-
tions were similarly successful. The last measurement series with
Fig. 2 Displacement ellipsoid representations of the crystal structures of 5-benzyloxytryptaminium dihydrogenphosphate (top left),
5-benzyloxytryptaminium tartrate (minor disordered parts and water molecules omitted for clarity, top right), 2-(3-(3,5-bis(triﬂuoromethyl)
phenyl)-thioureido)-N,N,N-trimethylethanaminium bromide (lower left) and (R)-carnitinenitrile tetraphenylborate (lower right). Ellipsoids are
drawn at 50% probability.
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100 nl analyte solution required really minute amounts of
material and still yielded high quality crystals (ESI Fig. 3†) that
directly led to publishable structures. As can be seen in Table 1,
the required amount essentially depends upon the solubility of
the compound in water. For our method, we work with solutions
that are 90% saturated. We used two procedures to obtain these
solutions: one was to determine the apparent solubility by
dissolution of the solid material and observing the progress with
amicroscope. The othermethod wasmuch simpler and used less
material: we generated a saturated stock solution, separated it
from the solid and diluted it then to 90% saturation.
The screening was performed with the seven mentioned
organic salts and mainly sodium salts of 77 diﬀerent counterions
(Table 2 and ESI†). The criteria for the selection of the counterions
were a known propensity to crystallize and/or being a compound
that is Generally Recognized As Safe (GRAS)36 for a potential later
use in an API. Each of the chosen 7 analytes was screened under
96 conditions, as some of the counterions were present in the
screening atmultiple, diﬀerent concentrations. The screening was
stopped aer 16 days; however longer equilibration times could
be applied. Quite oen the crystals formed aer a few days, see
e.g. the case of 5-benzyloxytryptaminium antimony-L-tartrate, in
which a change of crystal morphology could be observed (ESI
Fig. 2†). The same crystals could sometimes be observed in several
drops containing the same counterion at diﬀerent concentrations.
It was possible to determine 15 high quality single crystal struc-
tures of chemically diﬀerent salts directly from the screening
without the need for any further optimisation, and 14 of them
were novel structures. Additionally, 14 lead hits consisting of too
small crystals were manually recrystallized, which yielded in
7 cases big enough crystals that could bemeasured and rened by
SCXRD to give 7 novel structures (Fig. 2 and Table 2). In one
further case, covering the drop with oil induced the crystal growth
of the free base trazodone. The crystal nucleated at the oil/water
interface and then grew by penetrating into the oil. The three
compounds – [Bs]Br, [(+/)-Car]Cl and [()-Car]Cl – all having an
unusually high solubility of more than one gram per milliliter
were most challenging; obviously if the chloride is already present
at such high concentrations, it is diﬃcult to substitute it during
crystallization from a mixed chloride/anion solution.
Conclusion
Our screening method for the growth of single crystals con-
taining organic cations was very eﬀective: six out of seven tested
cationic moieties yielded at least one crystal structure. Also, the
primary screening used just a very small amount of material
(12 ml of a 90% saturated aqueous solution of a salt with an
organic cation) in order to test a total of 96 diﬀerent conditions,
and we were able to determine at least one unit cell directly in
most of the positive crystalline hits using in-house X-ray
diﬀractometers. Furthermore, the required manual work is
quite low due to the usage of a pipetting robot and a crystal
farm, both of which are available in many biochemical insti-
tutes and pharmaceutical companies. With just 26 mg of one
organic salt employing 100 nl of analyte solution per crystalli-
zation experiment, we were able to directly determine the
structure of 6 diﬀerent salts and obtained the lead to another 5
salts. The new screening method requires compounds that can
form stable cations in water and have a water solubility of at
least 2 mg ml1 of their salt form. We are currently working on
a system, which can crystallize less water soluble cations. In
contrast to the report of Berghausen,21 we were able to perform
a salt screening with highly water soluble compounds in
a purely aqueous environment. Performing the screening at
temperatures other than room temperature is possible and
yielded a second, unknown polymorph of enantiomerically pure
ephedrinium iodide.
Conﬂicts of interest
There are no conicts of interest to declare.
Acknowledgements
We thank Prof. Dr Mario Waser for kindly providing compound
[Cat]I, Lonza Ltd. Basel for providing the sodium dicyanamide,
and Beat Blattmann as well as Ce´line Stutz for setting up our
crystallization trials on the robot. We thank Mohammad Al-
Qatanani for determining the aqueous solubility of various
compounds by HPLC and Prof. Dr Anthony Linden for a critical
reading of the manuscript. We thank the University of Zu¨rich,
the R'Equip programme of the Swiss National Science Foun-
dation (project number 206021_164018) and the Czech Science
Foundation (grant No. 16-10035S) for nancial support.
References
1 M. von Raumer, J. Dannappel and R. Hilker, Chem. Today,
2006, 24, 41–44.
2 L. Kumar, A. Amin and A. K. Bansal, Drug Discovery Today,
2007, 12, 1046–1053.
3 W.-Q. Tong, in Developing Solid Oral Dosage Forms, ed. Y.
Chen, G. G. Z. Zhang, L. Liu and W. R. Porter, Academic
Press, San Diego, 2009, ch. 4, pp. 75–86.
4 N. Wyttenbach, B. Sutter and P. Hidber, in Handbook of
Pharmaceutical Salts, ed. P. H. Stahl and C. G. Wermuth,
Verlag Helvetica Chimica Acta, 2nd edn., 2011, ch. 8, pp.
203–233.
5 Pharmaceutical Salts and Co-crystals, ed. J. Wouters and
L. Que´re´, Royal Society of Chemistry, Cambridge, 2011.
6 S. R. Byrn, G. Zogra and X. Chen, J. Pharm. Sci., 2010, 99,
3665–3675.
7 D. P. Elder, R. Holm and H. L. de Diego, Int. J. Pharm., 2013,
453, 88–100.
8 G. S. Paulekuhn, J. B. Dressman and C. Saal, J. Med. Chem.,
2007, 50, 6665–6672.
9 B. Spingler, S. Schnidrig, T. Todorova and F. Wild,
CrystEngComm, 2012, 14, 751–757.
10 P. P. Nievergelt and B. Spingler, CrystEngComm, 2017, 19,
142–147.
11 Y. Inokuma, S. Yoshioka, J. Ariyoshi, T. Arai, Y. Hitora,
K. Takada, S. Matsunaga, K. Rissanen and M. Fujita,
Nature, 2013, 495, 461–466.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3716–3722 | 3721
Edge Article Chemical Science
12 Y. Inokuma, S. Yoshioka, J. Ariyoshi, T. Arai and M. Fujita,
Nat. Protoc., 2014, 9, 246–252.
13 M. Hoshino, A. Khutia, H. Xing, Y. Inokuma and M. Fujita,
IUCrJ, 2016, 3, 139–151.
14 T. R. Ramadhar, S.-L. Zheng, Y.-S. Chen and J. Clardy, Acta
Crystallogr., Sect. A: Found. Adv., 2015, 71, 46–58.
15 T. R. Ramadhar, S.-L. Zheng, Y.-S. Chen and J. Clardy,
CrystEngComm, 2017, 19, 4528–4534.
16 F. Sakurai, A. Khutia, T. Kikuchi andM. Fujita, Chem.–Eur. J.,
2017, 23, 15035–15040.
17 S. Lee, E. A. Kapustin and O. M. Yaghi, Science, 2016, 353,
808–811.
18 A. McPherson and J. A. Gavira, Acta Crystallogr., Sect. F:
Struct. Biol. Commun., 2014, 70, 2–20.
19 B. M. Collman, J. M. Miller, C. Seadeek, J. A. Stambek and
A. C. Blackburn, Drug Dev. Ind. Pharm., 2013, 39, 29–38.
20 M. R. Thorson, S. Goyal, B. R. Schudel, C. F. Zukoski,
G. G. Z. Zhang, Y. C. Gong and P. J. A. Kenis, Lab Chip,
2011, 11, 3829–3837.
21 P. B. Tarsa, C. S. Towler, G. Woollam and J. Berghausen, Eur.
J. Pharm. Sci., 2010, 41, 23–30.
22 E. A. Collier, R. J. Davey, S. N. Black and R. J. Roberts, Acta
Crystallogr., Sect. B: Struct. Sci., 2006, 62, 498–505.
23 J. DeFalco, D. Steiger, M. Dourado, D. Emerling and
M. A. J. Duncton, Bioorg. Med. Chem. Lett., 2010, 20, 7076–
7079.
24 C. R. Groom, I. J. Bruno, M. P. Lightfoot and S. C. Ward, Acta
Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater., 2016, 72,
171–179.
25 J. M. Leger, M. Gadret and A. Carpy, Acta Crystallogr., Sect. B:
Struct. Crystallogr. Cryst. Chem., 1978, 34, 3705–3709.
26 H. Puetter, E. Roske and H. J. Pander, German Pat.,
DE3419723A1, 1985.
27 K. Nakayama, H. Honda, Y. Ogawa, T. Ohta and T. Ozawa, US
Pat., US5041375, 1991.
28 M. Malaguarnera, Curr. Opin. Gastroenterol., 2012, 28, 166–
176.
29 M. Tiﬀner, J. Novacek, A. Busillo, K. Gratzer, A. Massa and
M. Waser, RSC Adv., 2015, 5, 78941–78949.
30 M. A. Bertucci, S. J. Lee and M. R. Gagne´, Chem. Commun.,
2013, 49, 2055–2057.
31 H. Wu, A. R. West, M. Vickers, D. C. Apperley and A. G. Jones,
Chem. Eng. Sci., 2012, 77, 47–56.
32 S. N. Black, E. A. Collier, R. J. Davey and R. J. Roberts,
J. Pharm. Sci., 2007, 96, 1053–1068.
33 G. Davidoﬀ, M. Guarracini, E. Roth, J. Sliwa and G. Yarkony,
Pain, 1987, 29, 151–161.
34 J. P. Fillers and S. W. Hawkinson, Acta Crystallogr., Sect. B:
Struct. Crystallogr. Cryst. Chem., 1979, 35, 498–500.
35 P. K. Mandal, B. Kauﬀmann, H. Destecroix, Y. Ferrand,
A. P. Davis and I. Huc, Chem. Commun., 2016, 52, 9355–9358.
36 SCOGS (Select Committee on GRAS Substances), https://
www.accessdata.fda.gov/scripts/fdcc/?set¼SCOGS, accessed
23rd October 2017.
3722 | Chem. Sci., 2018, 9, 3716–3722 This journal is © The Royal Society of Chemistry 2018
Chemical Science Edge Article
S1 
 
Electronic supplementary information for 
 
A high throughput screening method for the nano-crystallization of 
salts of organic cations 
 
Philipp P. Nievergelt, Martin Babor, Jan Čejka, Bernhard Spingler* 
 
*Corresponding author: spingler@chem.uzh.ch 
 
Content: 
1.  Materials and Methods 
1.1  Chemicals 
1.2  Stock Solutions including Supplementary Table 1 
1.3  Crystallization of Compounds incl. Supplementary Figures 1-3 
1.4  X-ray Single Crystal Diffraction  
2.  Description of the Structures including Supplementary Figures 4-26 and Supplementary Tables 2-8 
  
S2 
 
1. Materials and Methods: 
 
1.1. Chemicals 
5-benzyloxytryptamine hydrochloride ([BaH]Cl) was obtained from Acros Organics, Geel, Belgium. N-
Butylscopolammonium bromide (also described as butylscopolamine bromide or hyoscine butylbromide 
[Bs]Br), (1S,2R)-(+)-ephedrine hydrochloride ([(+)-EphH]Cl) and trazodone hydrochloride ([TrH]Cl) 
were obtained from Sigma Aldrich. (R,S)-carnitinenitrile chloride ([(+/-)-Car]Cl) was obtained from 
Frontier Scientific, Logan, UT, USA. (R)-carnitinenitrile chloride ([(-)-Car]Cl) was obtained from 
Angene Chemical, Hong Kong, HK. 2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-N,N,N-
trimethylethanammonium iodide ([Cat]I) was kindly provided by Prof. Dr. Mario Waser, Linz, Austria; it 
was prepared analogously as described in 1. The used water was doubly distilled. Sodium or potassium 
salts of counterions (SCI) were obtained from various commercial suppliers. If the sodium or potassium 
salts were not commercially available, the corresponding sodium salts were prepared by titration of the 
corresponding acids with a hydroxide sodium solution (2 M) until the pH reached 7. The solutions of 
newly prepared salts were concentrated with the help of a rotary evaporator and dried by lyophilisation at 
0.02 mbar. The water content was determined by elemental analysis (carbon, hydrogen and nitrogen) of 
the salt.  
 
1.2. Stock Solutions 
The stock solutions of (R,S)-carnitinenitrile chloride, (R)-carnitinenitrile chloride, (1S,2R)-(+)-ephedrine 
hydrochloride, trazodone hydrochloride and iodide catalyst were employed at 90% concentration of the 
saturated solutions. The approximate solubilities of (R,S)- and (R)-carnitinenitrile chloride were 
determined by slowly dissolving solid material in water in steps of 10 μl with intense stirring until a clear 
solution was observed under a microscope (see Supplementary Table 1).  
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Supplementary Table 1: Determination of apparent solubility of butylscopolamine bromide, 
carnitinenitrile chloride and trazodone hydrochloride by the dissolution method. 
 m 
[mg] 
Last step 
[µl] 
Total volume 
[µl] 
Approximate apparent 
solubility [mg / ml] 
butylscopolamine bromide 158 10 90 1800  ± 200 
(R,S)-carnitinenitrile chloride 78 10 70 1120  ± 160 
(R)-carnitinenitrile chloride 76 10 60 1300  ± 200 
trazodone hydrochloride 10 10 260 38.5  ± 0.2 
 
[Cat]I (5 mg), trazodone hydrochloride (35 mg) and 5-benzyloxytryptamine hydrochloride [BaH]Cl (20 
mg) were each suspended in water (1 ml). The suspensions were stirred at 22°C for 1 day, centrifuged and 
filtered through a sterile filter with a pore size of 0.20 μm to yield saturated solutions. Those were finally 
diluted with water in a volume ratio of 90:10 to yield 90% saturated solutions. The solubility of [BaH]Cl, 
[Cat]I and [EphH]Cl were determined by precisely weighing about 1 mg of material and dissolving it in a 
defined volume of a 1:1 mixture of water and methanol (just water for [EphH]Cl). With this stock 
solution, a calibration curve in a HPLC system was generated. The saturated aqueous solution was 
generated as described before, isolated and diluted ten-fold. The concentration of this solution was 
determined by HPLC using the previously generated calibration curve. The so determined solubilities 
were 2.2 ± 0.1 mg / ml for [BaH]Cl, 6.9 ± 0.1 mg / ml for [Cat]I and 257 ± 1 mg / ml for [EphH]Cl in 
water at 22°C. 
 
The concentrations of stock solutions of the sodium or potassium salts of counterions (SCI) were chosen 
such as that they were approximately half-saturated. For some highly soluble SCI, additional solutions 
were generated with lower concentrations. All stock solutions were filtered through sterile filters with a 
pore size of 0.20 μm. Solubility data were taken from the literature or determined experimentally. The 
approximate experimental solubility of the sodium or potassium SCI was determined at 22°C by slowly 
dissolving solid material (between 20 - 200 mg) in water (in steps of 10 - 20 μl) with intense stirring till a 
clear solution was observed under a microscope. The final concentration was calculated after the volume 
change of solutions caused by dissolving the solid salts was taken into consideration. Unfortunately, a few 
salts have some inappropriate physico-chemical properties and we had to use different approaches for 
preparing the stock solutions. 
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Disodium DL-tartrate is too hygroscopic to be isolated. A saturated solution was prepared (stirring the 
suspension for 48 h at 22°C) and this solution was diluted to 50%. The approximate molarity was 
calculated based on weight change (0.106 g) after drying in a rotary evaporator of 1 ml 50% solution (5 
hours, 60 °C and 68 mbar). The calculation of molarity was made with the molar mass of anhydrous 
disodium DL-tartrate (194.051 g/mol). 
 
Sodium pyrrolidone carboxylate, sodium hexanoate, sodium 2-ethylhexanoate and sodium octanoate all 
produce gels. Suitable viscous solutions of these salts were used like stock solutions. Sodium pyrrolidone 
carboxylate cannot be isolated as a powder due to its high hygroscopicity and approximate molarity was 
calculated based on weight change (0.749 g) after drying in the rotary evaporator 1 ml of the stock 
solution (5 hours, 60 °C and 68 mbar). The calculation of molarity was made with the molar mass of the 
anhydrous sodium pyrrolidone carboxylate (151.11 g/mol). 
 
Sodium DL-lactate and sodium L-lactate both produce gels. Solutions of sodium DL-lactate and sodium 
L-lactate were prepared with a concentration of 30% m (salt) / m (water) based on the concentration of 
commercially available solutions (50% solution).  
 
1.3. Crystallization of Compounds 
The principle of the vapour diffusion 2 is shown in Supplementary Fig. 1. The crystallization screening 
experiments were performed with the help of the Gryphon LCP nano-drop handler from Art Robbins 
Instruments in ARI Intelli-Plates 96-3 LVR. 100 - 500 nl of a stock solution of the to be crystallized cation 
were mixed with the same volume of the stock solutions of the SCI and equilibrated against 75 μl of the 
stock solution of the same SCI. Each cation was tested for crystallization in 96 wells, each well containing 
a different condition, and with 77 different SCI in total. Due to the high viscosity of some solutions, all 
pipetting was done with slow speed. Plates were incubated for 5 - 16 days at 20°C. At the beginning of the 
study, some plates were additionally incubated at 4°C. The Rock Imager 1000 took a picture of each well 
with normal light (immediately after setting up the plate and then after 2, 5, 10 and 16 days) and cross 
polarized light (immediately after setting up the plate and then after 5, 10 and 16 days) (see 
Supplementary Fig. 2).  
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Supplementary Figure 1: Adopted vapour diffusion technique for the crystallization of organic cations.
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Supplementary Figure 2: Pictures of the crystallization of 5-benzyloxytryptaminium antimony-L-tartrate 
from 5-benzyloxytryptaminium chloride and potassium antimony-L-tartrate (500 nl each). Pictures shown 
were taken immediately after setting up the plate (top left) and then after 2 (top right), 5 (bottom left) and 
16 (bottom right) days. 
If single crystals were observed during this incubation period, they were removed from the wells. In order 
to do so, wells with formed crystals were opened with a razor blade. Sometimes, the contents of the wells 
were then covered with oil (Infineum V8512, formerly known as Paratone N). The crystals were fished 
out with a nylon loop mounted on top of a CrystalCap Magnetic™ (Hampton Research), prepared on a 
glass slide under oil (Infineum V8512) and measured on a single crystal X-ray diffractometer. The quality 
of some crystalline material was too poor for structure determination by X-ray single crystal diffraction. 
These hits were then manually re-synthesized and re-crystallized to obtain better crystals. 
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Supplementary Figure 3: Pictures of the crystallization of ephedrine hydrobromide (left) from ephedrine 
hydrochloride and sodium bromide (100 nl each) and ephedrinium thiocyanide (right) from ephedrine 
hydrochloride and sodium thiocyanate (100 nl each). Pictures shown were taken after 5 days. 
 
1.4. X-ray Single Crystal Diffraction 
Single-crystal X-ray diffraction was measured on two diffractometers. The first one was a Rigaku-Oxford 
Diffraction XtaLAB Synergy-S dual source diffractometer: Kappa-axis four-circle goniometer with a 
Dectris Pilatus3 R 200K HPC (Hybrid Photon Counting) detector and Cu and Mo PhotonJet microfocus 
X-ray sources. The second one was a SuperNova dual source diffractometer: Kappa-axis four-circle 
goniometer with an Atlas electronic CCD area detector and Cu and Mo microfocus X-ray sources. 
Computing of measuring strategy and data reduction were performed with CrysAlisPro 3. The structures 
were solved with direct methods using SIR97 4 or the charge flipping method using Superflip 5. The 
structures were refined by full-matrix least-squares methods on F2 with SHELXL-2014 6 using the GUI 
ShelXle 7 or refined by least-squares methods on F2 with CRYSTALS 8. Graphical output was produced 
with the help of the program Mercury 9. CCDC 1585747-1585765 and 1823199-1823201 contain the 
Supplementary crystallographic data for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. 
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2. Description of the structures  
 
[5-benzyloxytryptaminium][chloride] 
Crystalline material was obtained from the screening (from a drop containing 500 nl of a 3.0 M sodium 
chloride and 500 nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution equilibrating 
against a reservoir of 3 M sodium chloride, as well as from a drop containing 500 nl of a 1.5 M sodium 
chloride and 500 nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution equilibrating 
against a reservoir of 1.5 M sodium chloride). The quality of the crystals from both experiments was too 
low for structure determination by SCXRD. The crystal used for SCXRD was crystallized from a mixture 
of 20 l of 3 M sodium chloride in water, 20 l of a 90% saturated solution of 5-benzyloxytryptamine 
hydrochloride in water and 80 l acetone. The crystallization technique was slow evaporation in an 1.5 ml 
Eppendorf vial. This complex crystallized in the monoclinic space group P21/c. The asymmetric unit 
consists of one 5-benzyloxytryptaminium cation, which is protonated at the amino group, and one chloride 
anion. The amino group makes three weak hydrogen bonds to three chloride anions (N1-H11 Cl21(x,1-y,-
z): 3.1834(16) Å; N1-H12 Cl21(x,1/2-y,1/2+z): 3.2310(15); N1-H13 Cl21(x,y,1+z): 3.1470(15) Å). 
  
Supplementary Figure 4: Left: displacement ellipsoid representation of [BaH]Cl, ellipsoids are drawn at 
50% probability. Right: packing diagram of [BaH]Cl. 
 
[5-benzyloxytryptaminium][iodide] 
Crystalline material was obtained from several crystallization setups: in one case, the drop obtained by 
mixing 500 nl of a 2.65 M sodium iodide and 500 nl of a 90% saturated 5-benzyloxytryptamine 
hydrochloride solution was equilibrated against a reservoir of 2.65 M sodium iodide. In two other setups, 
half and quarter concentrations of iodide in drops and reservoirs respectively were used. All these 
S9 
 
conditions gave crystals, but their quality was too low for structure determination by SCXRD. The crystal 
used for SCXRD was crystallized from a mixture of 20 l of 5.3 M sodium iodide in water, 20 l of a 
90% saturated solution of 5-benzyloxytryptamine hydrochloride in water and 80 l acetone. The 
crystallization technique was slow evaporation. This complex crystallized in the monoclinic space group 
P21/c. The asymmetric unit consists of one 5-benzyloxytryptamininum cation, which is protonated at the 
amino group, and an iodide counterion. The amino group forms three hydrogen bonds to iodide ion (N1-
H1 I21(-x,-1/2+y,1/2-z): 3.507(2) Å; N1-H12 I21: 3.562(2) Å; N1-H13 I21(x,3/2-y,1/2+z): 3.526(2) Å). 
  
Supplementary Figure 5: Left: displacement ellipsoid representation of [BaH]I, ellipsoids are drawn at 
50% probability. Right: packing diagram of [BaH]I. 
 
[5-benzyloxytryptaminium][dihydrogen phosphate] 
The crystalline material, which was obtained directly from the screening, was of insufficient quality for 
structure determination by SCXRD. The setup was either a drop obtained by mixing 500 nl of a 4 M 
sodium dihydrogen phosphate solution and 500 nl of a 90% saturated 5-benzyloxytryptamine 
hydrochloride solution that was equilibrated against a reservoir of 4 M sodium dihydrogen phosphate, or 
the same setup with half the sodium dihydrogen phosphate concentration. The crystal used for SCXRD 
was crystallized from a mixture of 20 l of 4 M sodium dihydrogen phosphate in water, 20 l of a 90% 
saturated solution of 5-benzyloxytryptamine hydrochloride in water and 80 l acetone. The crystallization 
technique was slow evaporation. This complex crystallized in the monoclinic space group P21/c. The 
asymmetric unit consists of one 5-benzyloxytryptaminium cation, which is protonated at the amino group, 
and a dihydrogen phosphate anion. The amino group forms three hydrogen bonds to oxygen atoms of 
dihydrogen phosphate (N1-H11 O22(x,3/2-y,-1/2+z): 3.2040(15) Å; N1-H13 O22: 2.9143(14) Å; N1-H12 
O24(2-x,1-y,1-z): 2.7683(15) Å). The nitrogen of the indole creates a hydrogen bond to the oxygen atom 
of the dihydrogen phosphate (N6-H61 O22: 2.9143(14) Å). 
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Supplementary Figure 6: Left: displacement ellipsoid representation of [BaH]H2PO4, ellipsoids are drawn 
at 50% probability. Right: packing diagram of [BaH]H2PO4. 
 
[5-benzyloxytryptaminium]2[antimony L-tartrate]·2(H2O) 
This crystal arose in a drop obtained by mixing 500 nl of a 54 mM potassium antimony L-tartrate and 500 
nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution, and equilibrating against a reservoir 
of 54 mM potassium antimony L-tartrate. This complex crystallized in the monoclinic space group C2. 
The asymmetric unit consists of half an antimony L-tartrate anion, one water molecule and one 5-
benzyloxytryptaminium cation, which is protonated at the amino group. The antimony L-tartrate lies on a 
two-fold axis. The amino group makes three hydrogen bonds to the antimony L-tartrate (N1-H12 O24: 
2.960(6) Å, N1-H13 O25(x,1+y,z): 2.983(5) Å and N1-H13 O31(x,1+y,z): 3.003(6) Å). 
  
Supplementary Figure 7: Left: displacement ellipsoid representation of [BaH]2[antimony L-
tartrate]·2(H2O), ellipsoids are drawn at 50% probability, for clarity only the asymmetric unit is shown. 
Right: packing diagram of [BaH]2[antimony L-tartrate]·2(H2O). 
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[5-benzyloxytryptaminium]2[L-tartrate]·3.35(H2O) 
This crystal was isolated from a drop obtained by mixing of 500 nl of a 1.4 M sodium potassium L-tartrate 
and 500 nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution, and equilibrating against a 
reservoir of 1.4 M sodium potassium L-tartrate. The salt crystallized in the chiral space group P21. In the 
asymmetric unit, there are two 5-benzyloxytryptaminium cations, one tartrate dianion and 3.35 water 
molecules. The ethylammonium group of one cation is disordered in a ratio of 70:30. The non-disordered 
ammonium group creates two hydrogen bonds to two carboxylate groups and one fully occupied water 
molecule. The disordered ammonium group forms two hydrogen bonds to two alcohol groups of one 
tartrate and one fully occupied water molecule. Because of the disorder, the hydrogen bonding pattern is 
not discussed in further detail. 
 
Supplementary Figure 8: Top: displacement ellipsoid representation of [BaH]2[L-tartrate]·3.35(H2O), 
ellipsoids are drawn at 50% probability. Only the major conformer of the disordered ethylammonium 
group is shown for clarity. Below: packing diagram of [BaH]2[L-tartrate]·3.35(H2O). 
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[5-benzyloxytryptaminium]2[oxalate]·2(H2O) 
This crystal was isolated from a drop obtained by mixing of 500 nl of a 140 mM disodium oxalate and 500 
nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution, and equilibrating against a reservoir 
of 140 mM disodium oxalate. This complex crystallized in the monoclinic space group P21. Refinement in 
P21/c yielded a model with a very high R value and high residual electron densities at irregular positions, 
hence, the final refinement was carried out in the non-isomorphic subgroup P21. The asymmetric unit 
consists of two 5-benzyloxytryptaminium cations, which are protonated at the amino position, one oxalate 
anion and two water molecules. The two water molecules as well as the oxalate anion are disordered in a 
ratio of 88:12. Both amino groups form 3 hydrogen bonds. The following discussion concentrates on the 
major component of the disorder: one ammonium (N1) group binds via two hydrogen bonds to two 
oxygen atoms of the oxalate (N1-H11 O43(-1+x,y,z): 2.718(2) Å and N1-H11 O41(-x,1/2+y,1-z): 
2.801(3) Å) and one to water molecule (N1-H11 O47(-x,-1/2+y,1-z): 2.974(2) Å). The second ammonium 
(N21) makes one hydrogen bond to the oxygen atom of the oxalate (N21-H211 O45 2.926(3) Å and to two 
water molecules (N21-H211 O46(-x,1/2+y,1-z): 2.800(2) Å and N21-H211 O48: 2.860(3) Å). One indole 
group forms a hydrogen bond to the oxygen atom of the oxalate (N6-H61 O43 2.906(2) Å). The second 
indole group creates a hydrogen bond to a water molecule (N26-H261 O47(1-x,-1/2+y,1-z): 2.976(2) Å).  
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Supplementary Figure 9: Top: displacement ellipsoid representation of [BaH]2[oxalate]·2(H2O), 
ellipsoids are drawn at 50% probability. Only the major components of the disordered moieties are shown 
for clarity. Below: packing diagram of [BaH]2[oxalate]·2(H2O). 
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[5-benzyloxytryptaminium]2[sulfate]·2(H2O) 
This crystal arose in a drop obtained by mixing of 500 nl of a 1 M sodium sulfate and 500 nl of a 90% 
saturated 5-benzyloxytryptamine hydrochloride solution, and equilibrating against a reservoir of 1 M 
sodium sulfate. The achiral salt crystallized in the chiral space group P21 with two 5-
benzyloxytryptaminium cations, one sulfate anion and two water molecules in the asymmetric unit. The 
two 5-benzyloxytryptaminium cations are protonated at the amino group. These aminium groups form 
multiple hydrogen bonds to two oxygen atoms of sulfate anions (N1-H11 O44(1-x,1/2+y,1-z): 2.769(3) Å; 
N1-H13 O45: 2.784(3) Å and N21-H211 O42 (1+x,y,z): 2.756(3) Å; N21-H213 O43(1-x,-1/2+y,1-z): 
2.756 (3) Å). Finally, one indole group forms a hydrogen bond to oxygen of sulfate ion (N26-H261 O42 
2.834(3) Å). 
 
Supplementary Figure 10: Top: displacement ellipsoid representation of [BaH]2[sulfate]·2(H2O), 
ellipsoids are drawn at 50% probability. Below: packing diagram of [BaH]2[sulfate]·2(H2O). 
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[5-benzyloxytryptaminium][tetrafluoroborate]  
The single crystal was isolated from a drop obtained by mixing 500 nl of a 4 M sodium tetrafluoroborate 
and 500 nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution, and equilibrating against a 
reservoir of 4 M sodium tetrafluoroborate. Crystals of equal quality could be obtained by taking 100 nl of 
both solutions instead. This complex crystallized in the monoclinic space group P21/c. The asymmetric 
unit consists of one 5-benzyloxytryptaminium cation, which is protonated at the amino group, and one 
tetrafluoroborate anion. This amino group binds to 4 fluorine atoms thus forming 2 two-centred hydrogen 
bonds and a combination of a three-centered hydrogen bond with a bifurcated hydrogen bond (N1-H11 
F25(2-x,1-y,1-z): 2.9192(14) Å; N1-H12 F22(x,3/2-y,1/2+z): 2.8544(15) Å; N1-H12 F25: 2.9182(14) Å; 
N1-H13 F24(2-x,-1/2+y,3/2-z): 2.8619(14) Å). 
  
Supplementary Figure 11: Left: displacement ellipsoid representation of [BaH][tetrafluoroborate], 
ellipsoids are drawn at 50% probability. Right: packing diagram of [BaH][tetrafluoroborate]. 
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[5-benzyloxytryptaminium][thiocyanate] 
This crystal was isolated from a drop obtained by mixing 500 nl of a 3.5 M potassium thiocyanate solution 
and 500 nl of a 90% saturated 5-benzyloxytryptamine hydrochloride solution equilibrating against a 
reservoir of 3.5 M potassium thiocyanate. This complex crystallized in the monoclinic space group P21/c. 
The asymmetric unit consists of one 5-benzyloxytryptaminium cation, which is protonated at the amino 
group, and a thiocyanate anion. The amino group forms a hydrogen bond to the nitrogen atom of the 
thiocyanate ion (N1-H12 N21(x, y, z-1): 2.7857(19) Å). 
Supplementary Figure 12: Top: displacement ellipsoid representation of [BaH][thiocyanate], ellipsoids 
are drawn at 50% probability. Below: packing diagram of [BaH][thiocyanate]. 
 
The crystal structures of [5-benzyloxytryptaminium]2[succinate] and [5-benzyloxytryptaminium] 
[bromide] will be described in a later publication. 
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[(R,S)-carnitinenitrile][tetraphenylborate] 
Crystalline material was obtained from the screening in drops containing either 200 mM sodium 
tetraphenylborate and 2.82 M (R,S)-carnitinenitrile chloride equilibrating against a reservoir of 400 mM 
sodium tetraphenylborate, or 100 mM sodium tetraphenylborate and 2.82 M (R,S)-carnitinenitrile chloride 
equilibrating against a reservoir of 200 mM sodium tetraphenylborate. The quality of the crystals was too 
low for structure determination by SCXRD. The measured crystal was obtained by recrystallization in 
acetone as follows: (R,S)-carnitinenitrile tetraphenylborate precipitated immediately after mixing a stock 
solution of sodium tetraphenylborate (2.82 M, 50 μl) and the stock solution of (R,S)-carnitinenitrile 
chloride (50 μl). This precipitate was filtered through a filter paper and dried on the very filter paper at 
room temperature. The dry powder material was dissolved in acetone till a clear solution was observed 
(around 100 μl acetone). The solution was evaporated at room temperature from an open vial. This 
complex crystallized in the monoclinic space group P21/n. The asymmetric unit consists of one 
carnitinenitrile cation and one tetraphenylborate anion. The molecule of carnitinenitrile is disordered and 
both enantiomers are almost in same position in a ratio of 22% R-enantiomer and 78% S-enantiomer. As 
the space group is centrosymmetric, no enantiomeric enrichment was observed. There is no hydrogen 
bonding present, as the hydroxy group of carnitinenitrile has no close acceptor. 
  
Supplementary Figure 13: Left: displacement ellipsoid representation of [(R,S)-
carnitinenitrile][tetraphenylborate], ellipsoids are drawn at 50% probability. Only the major conformer 
of the disordered hydroxy part is shown for clarity. Right: packing diagram of [(R,S)-
carnitinenitrile][tetraphenylborate]. 
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[(R)-carnitinenitrile][tetraphenylborate] 
Crystalline material was obtained from the screening in drops containing either 200 mM sodium 
tetraphenylborate and 2.82 M (R)-carnitinenitrile chloride equilibrating against a reservoir of 400 mM 
sodium tetraphenylborate, or 100 mM sodium tetraphenylborate and 2.82 M (R)-carnitinenitrile chloride 
equilibrating against a reservoir of 200 mM sodium tetraphenylborate. The quality of the crystals was too 
low for structure determination by SCXRD. The crystal used for SCXRD was crystallized on a petri dish 
by directly mixing two drops ethylene glycol solutions of (R)-carnitinenitrile chloride (10 μl, 45% of 
saturation) and sodium tetraphenylborate (10 μl, 25% of saturation). This mixture started to crystallize 
immediately and produced a good quality crystal. This complex crystallized in the orthorhombic space 
group P 212121. The asymmetric unit consists of one (R)-carnitinenitrile cation and a tetraphenylborate 
anion. There is no hydrogen bond present, as the hydroxy group of carnitinenitrile has no close acceptor. 
  
Supplementary Figure 14: Left: displacement ellipsoid representation of [(R)-
carnitinenitrile][tetraphenylborate], ellipsoids are drawn at 50% probability. Right: packing diagram of 
[(R)-carnitinenitrile][tetraphenylborate]. 
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2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-N,N,N-trimethylethanammonium bromide [Cat]Br 
This crystal grew in a drop, which was obtained by mixing 500 nl 4 M sodium bromide and 500 nl of a 
90% saturated aqueous [Cat]I solution, and equilibrating against a reservoir of 4 M sodium bromide. This 
complex crystallized in the monoclinic space group P21/c. The asymmetric unit consists of two Cat 
cations and two bromide anions. The amino groups of the thiourea form weak hydrogen bonds to the 
bromides (N3-H31 Br62: 3.4606(13) Å; N10-H101 Br62: 3.3343(13) Å; N33-H331 Br61: 3.4263(13) Å 
and N40-H401 Br61: 3.3701(14) Å). One trifluoromethyl group is disordered in each Cat cation. 
  
Supplementary Figure 15: Left: displacement ellipsoid representation of [Cat][bromide], ellipsoids are 
drawn at 50% probability, for clarity only the major component of the disordered trifluoromethyl groups 
unit is shown. Right: packing diagram of [Cat][bromide]. 
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2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-N,N,N-trimethylethanammonium-potassium bis-
(hexafluorophosphate) [Cat][K][PF6]2  
This single crystal was directly picked from a drop obtained by mixing 500 nl 240 mM potassium 
hexafluorophosphate and 500 nl of a 90% saturated aqueous [Cat]I solution, and equilibrating against a 
reservoir of 240 mM potassium hexafluorophosphate. This complex crystallized in the monoclinic space 
group P21/c. The asymmetric unit consists of one Cat cation, one potassium cation and two 
hexafluorophosphate anions. Therefore the structure is actually a double salt. The amino groups of 
thiourea form hydrogen bonds with sulfur of thiourea (N3-H31 S1(x,3/2-y,-1/2+z): 3.488(2) Å and N10-
H101 S1(x,3/2-y,-1/2+z): 3.398(2) Å). The potassium cation is bonded to 9 flourine atoms. Such 
arrangements of K[PF6]43- have been reported previously 10-12. 
 
Supplementary Figure 16: Top: displacement ellipsoid representation of 
[Cat][potassium][hexafluorophosphate]2, ellipsoids are drawn at 50% probability. Below: packing 
diagram of [Cat][potassium][hexafluorophosphate]2. 
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[(1S,2R)-(+)-Ephedrinium][chloride] 
This single crystal was grown in a drop obtained by mixing 100 nl of a 3.0 M sodium chloride solution 
and 100 nl of a 1.12 M (1S,2R)-(+)-ephedrine hydrochloride solution, and equilibrating against a reservoir 
of 3.0 M sodium chloride. The complex crystallized in the monoclinic, chiral space group P21. with the 
unit cell constants a = 7.2565(3) Å, b = 6.1232(3) Å, c = 12.5570(6) Å and  = 102.256(5)°. The structure 
of the other enantiomer [(1R,2S)-(-)-ephedrinium][chloride] (a = 7.2557(3) Å, b = 6.1228(3) Å, c = 
12.5486(6) Å and  = 102.223(2)°) was previously reported 13. 
 
Supplementary Figure 17: Top: displacement ellipsoid representation of [(1S,2R)-(+)-
ephedrinium][chloride], ellipsoids are drawn at 50% probability. Below: packing diagram of [(1S,2R)-
(+)-ephedrinium][chloride]. 
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[(1S,2R)-Ephedrinium][bromide] 
This single crystal was grown in a drop obtained by mixing 100 nl of a 4.0 M sodium bromide solution 
and 100 nl of a 1.12 M (1S,2R)-(+)-ephedrine hydrochloride solution, and equilibrating against a reservoir 
of 3.0 M sodium bromide. The complex crystallized in the monoclinic, chiral space group P21. with the 
unit cell constants  a = 7.4467(2) Å, b = 6.20961(16) Å, c = 12.5863(4) Å and  = 101.176(3)°. The cell 
constants of the opposite enantiomer [(1R,2S)-ephedrinium][bromide] at room temperature were 
previously reported as follows: a = 12.74 Å, b = 6.20 Å, c = 7.62 Å and  = 100.80° 14. The structure is 
isostructural compared with the chloride salt (see the previous structure and ref. 13). 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 18: Top: displacement ellipsoid representation of [(1S,2R)-
ephedrinium][bromide], ellipsoids are drawn at 50% probability. Below: packing diagram of [(1S,2R)-
ephedrinium][bromide].  
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[(1S,2R)-Ephedrinium][iodide], polymorph II 
Crystals were obtained in a drop containing 2.67 M sodium iodide and 0.31 M (1S,2R)-(+)-ephedrine 
hydrochloride that was equilibrated by vapour diffusion against a reservoir of 5.34 M sodium iodide at 
4°C. The complex crystallized in the monoclinic, chiral space group P21. with the unit cell constants a = 
5.40542(18) Å, b = 6.94898(18) Å, c = 16.0701(4) Å and  = 95.864(3)°. This new crystal form is a 
polymorph of the previously reported orthorhombic form of the opposite enantiomer [(1R,2S)-
ephedrinium][iodide] (a = 25.66 Å, b = 7.33 Å, c = 19.14 Å), which was published in 1933 14. This 
orthorhombic crystal form was originally prepared in 1909 by evaporation of an ethanolic solution of 
[(1R,2S)-ephedrinium][iodide] 15.  
Supplementary Figure 19: Top: displacement ellipsoid representation of [(1S,2R)-ephedrinium][iodide], 
polymorph II, ellipsoids are drawn at 50% probability. Below: packing diagram of [(1S,2R)-
ephedrinium][iodide], polymorph II. 
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[(1S,2R)-Ephedrinium][iodide], polymorph I 
Crystals of polymorph I were obtained by mixing 1 ml of a 0.62 M solution of (1S,2R)-(+)-ephedrine 
hydrochloride and 1 ml of a 5.34 M solution of sodium iodide. Large crystals grew overnight 
(Supplementary Fig. 20). A suitable single crystal was chosen for the X-ray diffraction experiment. The 
unit cell was essentially equal to that found for the opposite enantiomer, which had already been reported 
in 1933 (see also the previous discussion of the other polymorph) 14. The complex crystallized in the 
orthorhombic, chiral space group P212121 and contained three molecules in the asymmetric unit. 
 
Supplementary Figure 20: Microscope picture of crystals grown in a 15 ml polypropylene centrifuge tube 
by mixing 1 ml of a 0.62 M solution of (1S,2R)-(+)-ephedrine hydrochloride and 1 ml of a 5.34 M solution 
of sodium iodide. The scale bar corresponds to 1 mm. 
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Supplementary Figure 21: Top: displacement ellipsoid representation of the asymmetric unit of [(1S,2R)-
ephedrinium][iodide], polymorph I, ellipsoids are drawn at 50% probability. Below: packing diagram of 
[(1S,2R)-ephedrinium][iodide], polymorph I.  
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[(1S,2R)-Ephedrinium]2[oxalate] 
Crystals were obtained from a drop containing 0.069 M disodium oxalate and 0.155 M (1S,2R)-(+)-
ephedrine hydrochloride that was equilibrated by vapour diffusion against a reservoir of 0.138 M 
disodium oxalate. The crystals were of sufficient size and excellent quality that they could even be 
measured with the relatively weak molybdenum X-ray radiation. The complex crystallized in the 
monoclinic, chiral space group C2. The asymmetric unit contains one protonated ephedrine cation and one 
half an of oxalate anion. Because of the used X-ray wavelength and the presence of exclusively light 
elements, the Flack x and the Parson's z parameters calculated by Platon 16 were unreliable (0.2(2) and 
0.15(19) respectively), however using the Hooft method 17 and assuming no racemic twinning gave a very 
low probability p2(wrong) of 1.2•10-4 that the model assumes the wrong enantiomer. As the program 
Platon only calculates p2(right), p2(wrong) was calculated with the formula given at 
http://www.absolutestructure.com/faq: p2(wrong) = [p3(wrong)/(p3(wrong) + p3(right))]). The protonated 
secondary amine forms two hydrogen bonds (N1-H11 O11: 2.7536(14) Å and N1-H12 O11(-x+1/2,y-1/2,-
z+1): 2.8233(14) Å) and the alcohol one hydrogen bond (O1-H1A O1(-x,y-1,-z+1): 2.6730(13) Å). 
  
Supplementary Figure 22: Left: displacement ellipsoid representation of [(1S,2R)-
ephedrinium]2[oxalate], ellipsoids are drawn at 50% probability. One protonated ephedrine cation and a 
whole oxalate anion are shown. Right: packing diagram of [(1S,2R)-ephedrinium]2[oxalate]. 
  
  
S27 
 
[(1S,2R)-Ephedrinium][thiocyanate] 
This single crystal was directly picked from a drop obtained by mixing 100 nl of a 1.75 M potassium 
thiocyanate solution and 100 nl of a 1.12 M (1S,2R)-(+)-ephedrine hydrochloride solution, and 
equilibrating against a reservoir of 1.75 M potassium thiocyanate. The complex crystallized in the 
orthorhombic, chiral space group P212121. with the unit cell constants  a = 6.09862(6) Å, b = 7.52704(9) Å 
and c = 27.3811(3)Å.  
 
Supplementary Figure 23: Top: displacement ellipsoid representation of [(1S,2R)-
ephedrinium][thiocyanate], ellipsoids are drawn at 50% probability. Below: packing diagram of 
[(1S,2R)-ephedrinium][thiocyanate]. 
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[Trazodonium][iodide] 
Crystals of the iodide salt were grown in a drop obtained by mixing 500 nl 5.34 M NaI and 500 nl of a 
90% saturated aqueous trazodone hydrochloride solution, and equilibrating against a reservoir of 5.34 M 
NaI. The asymmetric unit contains one protonated trazodone cation and an iodide anion. The trazodone 
cation is monoprotonated at the piperazine amine atom that is connected solely to aliphatic carbon atoms. 
This ammonium group forms a weak hydrogen bond to the iodide anion (N14-H14A I31: 3.6541(15) Å). 
  
Supplementary Figure 24: Left: displacement ellipsoid representation of [trazodonium][iodide], 
ellipsoids are drawn at 50% probability. Right: packing diagram of [trazodonium][iodide]. 
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[Trazodonium]2[oxalate]·10(H2O) 
This crystal was obtained at 4°C from a drop containing 69 mM Na2oxalate and 12 mM trazadone 
hydrochloride equilibrating against a reservoir of 138 mM Na2oxalate. This complex crystallized in the 
monoclinic space group I2/a. The asymmetric unit consists of one trazodonium cation, half an oxalate 
dianion and 6 sites for water molecules, of which 2 are half occupied. The trazodone cation is 
monoprotonated at the piperazine amine atom that is connected solely to aliphatic carbon atoms. This 
ammonium unit forms a double bifurcated hydrogen bond to the oxalate anion (N14-H14A O28: 
2.7510(17) Å and N14-H14A O29(-x+1, -y+1, -z+1): 2.9474(17) Å respectively). The oxalate anion sits 
on an inversion center, it is sandwiched between two ammonium units of the trazodone. 
 
Supplementary Figure 25: Top: displacement ellipsoid representation of 
[trazodonium]2[oxalate]·10(H2O), ellipsoids are drawn at 50% probability. One molecule of a protonated 
trazodone and a whole oxalate molecule is shown (see also paragraph above for a further discussion of the 
content of the asymmetric unit). Below: packing diagram of [trazodonium]2[oxalate]·10(H2O)]. 
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Trazodone·2(H2O) 
This crystal was obtained from a solution containing 141 mM disodium-(DL)-tartrate and 23.5 mM 
trazodone that was equilibrated by vapour diffusion against a reservoir of 242 mM disodium-(DL)-tartrate. 
After covering the drop with oil (Infineum V8512, formerly known as Paratone N), crystals started to 
form at the interface between the oil and the aqueous phase and grew into the oil. The asymmetric unit 
contains one neutral trazodone molecule and two water molecules, one is disordered over 2 positions 
(ratio 1:1), the other is disordered over 3 positions (ratio 5:4:1). In addition, the triazolo-pyridinone ring is 
disordered in a 9:1 ratio. 
 
 
Supplementary Figure 26: Top: displacement ellipsoid representation of trazodone·2(H2O), ellipsoids are 
drawn at 50% probability. For clarity, the disordered minor component of the trazodone molecules and the 
disordered water molecules are omitted. Below: packing diagram of trazodone·2(H2O). 
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Supplementary Table 2. Composition and concentration of the counterion salts in the 96 wells of the 
organic cation crystallization screen. 
Well number Chemical name Conc. [M] 
1 Sodium chloride 3.00 
2 Sodium chloride 1.50 
3 Sodium bromide 4.00 
4 Sodium bromide 2.00 
5 Sodium iodide 5.30 
6 Sodium iodide 2.50 
7 Sodium iodide 1.25 
8 Potassium thiocyanate 7.30 
9 Potassium thiocyanate 3.50 
10 Potassium thiocyanate 1.75 
11 Sodium dicyanamide 0.70 
12 Sodium tetrafluoroborate 4.00 
13 Sodium tetrafluoroborate 2.00 
14 Potassium hexafluorophosphate 0.24 
15 Sodium tetraphenylborate 0.40 
16 Sodium tetraphenylborate 0.20 
17 Disodium sulfate 1.00 
18 Sodium methanesulfonate 3.60 
19 Sodium methanesulfonate 1.80 
20 Sodium triflate 0.80 
21 Sodium isethionate 2.20 
22 Sodium isethionate 1.10 
23 Sodium (+/-)-camphorsulfonate 2.28 
24 Sodium benzenesulfonate 0.98 
25 Sodium 3-nitrobenzensulfonate 0.42 
26 Sodium p-toluenesulfonate 0.15 
27 Sodium 1-naphthalensulfonate 0.35 
28 Sodium 2-naphthalensulfonate 0.13 
29 Disodium 2,6-naphthalenedisulfonate 0.085 
30 Sodium nitrate 4.60 
31 Sodium nitrate 2.30 
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32 Sodium benzoate 1.80 
33 Sodium salicylate 2.20 
34 Sodium salicylate 1.10 
35 Sodium 4-aminosalicylate dihydrate 1.50 
36 Sodium meta-hydroxybenzoate 1.30 
37 Sodium nicotinate 2.96 
38 Sodium nicotinate 1.48 
39 Potassium hydrogen phthalate 0.27 
40 Disodium isophthalate 1.40 
41 Disodium terephthalate 0.060 
42 Disodium pamoate 0.050 
43 Sodium formate 6.00 
44 Sodium formate 3.00 
45 Sodium acetate 2.60 
46 Sodium trifluoroacetate 2.40 
47 Sodium 2-phenylpropionate 1.70 
48 Sodium DL-mandelate 0.25 
49 Sodium D-mandelate 0.25 
50 Sodium L-mandelate 0.25 
51 Sodium 1-naphthalenacetate 0.43 
52 Sodium diphenylacetate 0.33 
53 Sodium N-acetylglycinate 2.28 
54 Sodium hippurate 1.46 
55 Sodium pyrrolidone carboxylate 4.96 
56 Sodium propionate 5.20 
57 Sodium propionate 2.60 
58 Sodium DL-lactate 3.42 
59 Sodium L-lactate 3.42 
60 Sodium pyruvate 3.00 
61 Sodium pyruvate 1.50 
62 Sodium valerate 3.19 
63 Sodium hexanoate 2.70 
64 Sodium 2-ethylhexanoate 4.20 
65 Sodium 2-ethylhexanoate 2.10 
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66 Potassium gluconate 1.10 
67 Sodium octanoate 1.56 
68 Sodium hydrogen carbonate 0.60 
69 Disodium carbonate 1.00 
70 Disodium oxalate 0.14 
71 Disodium malonate 2.97 
72 Disodium succinate 1.13 
73 Disodium maleate 0.66 
74 Disodium fumarate 0.73 
75 Disodium DL-malate 2.27 
76 Disodium L-malate 2.92 
77 Sodium potassium L-tartrate 1.40 
78 Disodium DL -tartrate 0.55 
79 Disodium L-tartrate 1.00 
80 Disodium (+)-O,O'-dibenzoyl-D-tartrate 0.26 
81 Potassium antimony tartrate 0.054 
82 Disodium N-acetylglutamate 1.63 
83 Disodium adipate 1.19 
84 Potassium D-saccharate 0.050 
85 Trisodium citrate dihydrate 0.90 
86 Sodium DL-aspartate 0.25 
87 Sodium L-aspartate 0.25 
88 Sodium L-glutamate 2.00 
89 Sodium L-glutamate 1.00 
90 Sodium diethyldithiocarbamate 0.011 
91 Sodium saccharine 1.57 
92 Disodium hydrogen phosphate 0.43 
93 Sodium dihydrogen phosphate 4.00 
94 Sodium dihydrogen phosphate 2.00 
95 Disodium citrate 0.93 
96 Trisodium phosphate (dodecahydrate) 0.36 
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Supplementary Table 3: Crystallographic data of the chloride, iodide, dihydrogenphosphate and antimony-
L-tartrate salts of 5-benzyloxytryptaminium. 
name [BaH][chloride] [BaH][iodide] [BaH][dihydrogen 
phosphate] 
[BaH]2
[antimony L-
tartrate]·2(H2O)
Empirical formula [C17H19N2O]Cl [C17H19N2O]I
[C17H19N2O] 
[H2O4P] 
[C17H19N2O]2 
[C8H4O12Sb2] 
·2(H2O)
Diffractometer Synergy Synergy Synergy Synergy
Wavelength (Å) 1.54180 1.54180 1.54180 1.54180
mol. weight (g/mol) 302.80 394.26 364.34 1106.34
Crystal system monoclinic monoclinic monoclinic monoclinic
Space group P21/c P21/c P21/c C2
a (Å)  18.7661(5) 19.6674(3) 20.7561(2) 22.3684(7)
b (Å) 8.8339(2) 8.1224(1) 9.5134(1) 8.4156(1)
c (Å) 9.6084(3) 10.8447(2) 8.5352(1) 15.6852(4)
α (°) 90 90 90 90
β (°)  100.318(3) 105.2892(16) 96.5078(9) 130.585(5)
γ (°)  90 90 90 90
Volume (Å3) 1567.10(7) 1671.09(5) 1674.51(3) 2242.36(19)
Z 4 4 4 2
Density(calc.) (g/cm3) 1.283 1.567 1.445 1.639
Linear abs. coeff.  
(mm-1) 2.152 15.054 1.741 10.200
F(000) 640.0 784.0 768.0 1112.0
Crystal size (mm3) 0.26 × 0.15 × 0.02 0.56 × 0.44 × 0.02 0.23 × 0.15 × 0.01 0.39 × 0.03 × 0.01
Crystal description plate, colorless plate, colorless plate, colorless lath, colorless
θ range (°) 4.790; 74.494 4.662; 74.462 4.288; 75.865 3.711; 78.973
Reflections collected 30743 33730 34497 22761
Indep. reflections 
3187
[Rint = 0.0435]
3418
[Rint = 0.0527]
3487 
[Rint = 0.0301] 
4676
[Rint = 0.0948]
Reflections obs. 2941 3145 3276 4563
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I) I > 2.0σ(I)  I > 2.0σ(I) 
Completeness to θ (°) 0.999 to 74.494 1 to 74.462 0.999 to 75.865 0.998 to 77.394
Absorption corr. multi-scan multi-scan multi-scan  multi-scan 
Min. and max. transm. 0.74 and 0.96 0.02 and 0.73 0.44 and 0.98 0.25 and 0.89
Reflections / restraints / 
parameters 3187 / 0 / 190 3418 / 0 / 190 3487 / 0 / 226 4676 / 5 / 290
Goodness-of-fit on F2 0.9683 0.9797 0.9648 0.9417
Final R indices [I > 
2.0σ(I)] 
R1 = 0.0381
wR2 = 0.0949
R1 = 0.0226
wR2 = 0.0605
R1 = 0.0294 
wR2 = 0.0750 
R1 = 0.0453
wR2 = 0.1189
R indices (all data) R1 = 0.0406wR2 = 0.0965
R1 = 0.0246
wR2 = 0.0622
R1 = 0.0312 
wR2 = 0.0761 
R1 = 0.0458
wR2 = 0.1194
Final ρmax,min (e– /Å3) 0.42 and −0.37 1.01 and −0.50 0.25 and −0.38 2.37 and −0.68
Flack parameter not applicable not applicable not applicable -0.010(9)
CSD number 1585748 1585750 1585749 1585752
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Supplementary Table 4: Crystallographic data of the L-tartrate, oxalate, sulfate, tetrafluoroborate and 
thiocyanate salts of 5-benzyloxytryptaminium. 
name [BaH]2 
[L-tartarate] 
·3.35(H2O) 
[BaH]2[oxalate]
·2(H2O)
[BaH]2[sulfate]
·2 (H2O)
[BaH] 
[tetrafluoro-
borate] 
[BaH] 
[thiocyanate]
Empirical 
formula 
[C17H19N2O]2 
[C4H4O6] 
·3.35(H2O) 
[C17H19N2O]2 
[C2O4]·2(H2O)
[C17H19N2O] 
[O4S]·2(H2O)
[C17H19N2O] 
[BF4] 
[C17H19N2O]
[NCS]
Diffractometer Synergy Synergy Synergy Synergy Synergy
Wavelength 
(Å) 1.54180 1.54180 1.54180 1.54180 1.54180
mol. weight 
(g/mol) 742.37 654.72 666.80 354.15 325.43
Crystal system monoclinic monoclinic monoclinic monoclinic monoclinic
Space group P21 P21 P21 P21/c P21/c
a (Å)  8.8100(1) 9.0081 (1) 8.6454 (1) 19.5805 (2) 19.8981 (7)
b (Å) 9.7133(2) 9.3218 (1) 9.4630 (1) 9.7595 (1) 8.0213 (2)
c (Å) 21.7147(4) 19.4957 (2) 20.0392 (2) 8.9644 (1) 10.8806 (3)
α (°) 90 90 90 90 90
β (°)  100.1689(16) 95.3510 (9) 96.7530 (9) 103.1581 (12) 100.435 (3)
γ (°)  90 90 90 90 90
Volume (Å3) 1829.03(6) 1629.95 (3) 1628.06 (3) 1668.08 (3) 1707.92 (9)
Z 2 2 2 4 4
Density(calc.) 
(g/cm3) 1.349 1.334 1.360 1.410 1.266
Linear abs. 
coeff. (mm-1) 0.83 0.783 1.373 1.013 1.739
F(000) 789.6 692.0 708.0 736.0 688.0
Crystal size 
(mm3) 
0.08 × 0.06 × 
0.007 
0.11 × 0.10 ×
 0.02
0.08 × 0.05 × 
0.03
0.26 × 0.24 × 
0.01 
0.12 × 0.07 × 
0.02
Crystal 
description plate, colorless plate, colorless plate, colorless plate, colorless plate, colorless
θ range (°) 4.137; 74.489 4.556; 74.493 4.444; 74.500 4.638; 74.504 4.519; 74.390
Reflections 
collected 31303 34550 34569 18232 10335
Indep. 
reflections 
7406 
[Rint = 0.0442] 
6622
[Rint = 0.0325]
6613
[Rint = 0.0414]
3411 
[Rint = 0.0336] 
3450
[Rint = 0.0220]
Reflections 
obs. 6788 6365 6209 3088 2987
Criterion for 
obs. I > 2.0σ(I)  I > 2.0σ(I) I > 2.0σ(I) I > 2.0σ(I)  I > 2.0σ(I) 
Completeness 
to θ (°) 0.999 to 67.680 0.997 to 74.493 0.999 to 74.500 1.000 to 74.504 0.995 to 74.390
Absorption 
corr. gaussian multi-scan multi-scan multi-scan multi-scan 
Min. and max. 
transm. 0.803 and 1 0.67 and 0.98 0.81 and 0.97 0.21 and 0.99 0.83 and 0.97
Reflections / 
restraints / 7406 / 21 / 526 6622 / 67 / 516 6613 / 5 / 425 3411 / 0 / 226 3450 / 0 / 208
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parameters 
Goodness-of-
fit on F2 1.049 0.9838 0.9540 0.9896 0.9770
Final R ind. [I 
> 2.0σ(I)] 
R1 = 0.0411 
wR2 = 0.1118 
R1 = 0.0344
wR2 = 0.0973
R1 = 0.0417
wR2 = 0.1038
R1 = 0.0361 
wR2 = 0.0942 
R1 = 0.0338
wR2 = 0.0819
R indices (all 
data) 
R1 = 0.0451 
wR2 = 0.1144 
R1 = 0.0356
wR2 = 0.0984
R1 = 0.0441
wR2 = 0.1063
R1 = 0.0399 
wR2 = 0.0971 
R1 = 0.0401
wR2 = 0.0873
Final ρmax,min 
(e– /Å3) 0.51 and -0.37 0.31 and −0.24 0.80 and −0.39 0.28 and −0.21 0.38 and −0.26
Flack 
parameter -0.11(8) 0.17(14) 0.114(15) not applicable not applicable
CSD number 1585755 1585751 1585754 1585747 1585753
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Supplementary Table 5: Summary of crystals containing carnitinenitrile 
name [(+/-)-Car][tetraphenylborate] [(-)-Car][tetraphenylborate] 
Empirical formula [C7H15N2O][C24H20B] [C7H15N2O][C24H20B] 
Diffractometer Xcalibur SuperNova 
Wavelength (Å) 0.71073 1.5418 
mol. weight (g/mol) 462.44 462.44 
Crystal system monoclinic orthorhombic 
Space group P21/n P212121 
a (Å)  10.1433 (4) 9.49835 (14) 
b (Å) 18.6189 (6) 11.89113 (17) 
c (Å) 14.0467 (5) 22.8675 (3) 
α (°) 90 90 
β (°)  99.569 (3) 90 
γ (°)  90 90 
Volume (Å3) 2615.91 (16) 2582.79 (6) 
Z 4 4 
Density(calc.) (g/cm3) 1.174 1.189 
Linear abs. coeff. (mm-1) 0.070 0.542 
F(000) 992.0 992.0 
Crystal size (mm3) 0.48 × 0.46 × 0.05 0.43 × 0.10 × 0.09 
Crystal description plate, colorless prism, colorless 
θ range (°) 2.311; 30.505 3.866; 74.454 
Reflections collected 33386 21298 
Indep. reflections 7988 [Rint = 0.0359] 5254 [Rint = 0.0260] 
Reflections obs. 6470 5101 
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I)  
Completeness to θ (°) 1.000 to 30.505 1.000 to 74.454 
Absorption corr multi-scan multi-scan  
Min. and max. transm. 0.99 and 1.00 0.69 and 0.95 
Reflections / restraints / 
parameters 7983 / 128 / 407 5254 / 0 / 316 
Goodness-of-fit on F2 1.0133 0.9920 
Final R ind. [I > 2.0σ(I)] R1 = 0.0578, wR2 = 0.1365 R1 = 0.0272, wR2 = 0.0703 
R indices (all data) R1 = 0.0721, wR2 = 0.1480 R1 = 0.0281, wR2 = 0.0713 
Final ρmax,min (e– /Å3) 0.47 and −0.46 0.21 and −0.11 
Flack parameter not applicable 0.0(3) 
CSD number 1585762 1585761 
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Supplementary Table 6: Crystallographic summary of the crystals containing 2-(3-(3,5-
bis(trifluoromethyl)phenyl)-thioureido)-N,N,N-trimethylethanammonium (Cat) 
name [Cat][bromide] [Cat][potassium] 
[hexafluorophosphate]2 
Empirical formula [C14H18F6N3S]Br [C14H18F6N3S]K[F6P]2 
Diffractometer Synergy Synergy 
Wavelength (Å) 1.54180 1.54180 
mol. weight (g/mol) 454.27 703.39 
Crystal system monoclinic monoclinic 
Space group P21/c P21/c 
a (Å)  10.9874 (1) 24.3732 (2)  
b (Å) 14.2737 (1) 10.4084 (1)  
c (Å) 23.2106 (1) 9.9932 (1) 
α (°) 90 90 
β (°)  90.2783 (5) 93.1701 (9) 
γ (°)  90 90 
Volume (Å3) 3640.10 (4) 2531.26 (4) 
Z 8 4 
Density(calc.) (g/cm3) 1.658 1.846 
Linear abs. coeff. (mm-1) 4.736 5.196 
F(000) 1824.0 1400.0 
Crystal size (mm3) 0.48 × 0.13 × 0.06 0.11 × 0.05 × 0.02 
Crystal description lath, colorless lath, colorless 
θ range (°) 3.635; 72.121 3.632; 74.496 
Reflections collected 46471 49106 
Indep. reflections 7149 [Rint = 0.0269] 5098 [Rint = 0.0450] 
Reflections obs. 6871 4507 
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I)  
Completeness to θ (°) 0.995 to 72.121 0.987 to 74.33 
Absorption corr. multi-scan multi-scan  
Min. and max. transm. 0.11 and 0.76 0.64 and 0.92 
Reflections / restraints / 
parameters 7149 / 22 / 535 5098 / 79 / 408 
Goodness-of-fit on F2 1.0022 1.0134 
Final R ind. [I > 2.0σ(I)] R1 = 0.0221, wR2 = 0.0551 R1 = 0.0441, wR2 = 0.1053  
R indices (all data) R1 = 0.0230, wR2 = 0.0556 R1 = 0.0496, wR2 = 0.1087 
Final ρmax,min (e– /Å3) 0.50 and −0.41 0.84 and −0.48 
CSD number 1585756 1585757 
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Supplementary Table 7: Crystallographic data of crystals containing ephedrinium chloride, bromide and 
iodide (form II) salts. 
name [(+)-EphH][chloride] [(+)-EphH][bromide] [(+)-EphH][iodide], 
form II 
Empirical formula [C10H16CNO]Cl [C10H16NO]Br [C10H16NO]I
Diffractometer Synergy Supernova Synergy
Wavelength (Å) 0.71073 0.71073 1.54184
mol. weight (g/mol) 201.69 246.15 293.14
Crystal system monoclinic monoclinic monoclinic 
Space group P21 P21 P21 
a (Å)  7.2565(3) 7.4467(2) 5.40542(18) 
b (Å) 6.1232(3) 6.20961(16) 6.94898(18) 
c (Å) 12.5570(6) 12.5863(4) 16.0701(4) 
α (°) 90 90 90 
β (°)  102.256(5) 101.176(3) 95.864(3) 
γ (°)  90 90 90 
Volume (Å3) 545.23(4) 570.96(3) 600.47(3) 
Z 2 2 2
Density(calc.) (g/cm3) 1.229 1.432 1.621 
Linear abs. coeff. (mm-1) 0.314 3.565 20.679 
F(000) 216 252 288 
Crystal size (mm3) 0.40 × 0.08 × 0.04 0.41 × 0.07 × 0.05 0.25 × 0.06 × 0.011 
Crystal description colourless needle needle, colorless plate, colorless
θ range (°) 2.873; 32.767 2.952; 32.888 5.535; 74.157
Reflections collected 7304 9436 7652 
Indep. reflections 3239 [Rint = 0.0287]
3804 
[Rint = 0.0227]
2282
[Rint = 0.0330] 
Reflections obs. 2969 3388 2164
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I) I > 2.0σ(I)
Completeness to θ (°) 99.8 % to 25.242° 99.8 % to 25.242° 0.978 to 67.684
Absorption corr. multi-scan gaussian gaussian
Min. and max. transm. 0.74501 and 1 0.543 and 1 0.215 and 0.993
Reflections / restraints / 
parameters 3239 / 1 / 121 3804 / 1 / 121 2282 / 1 / 121
Goodness-of-fit on F2 1.059 1.045 1.075 
Final R ind. [I > 2.0σ(I)] R1 = 0.0302wR2 = 0.0722
R1 = 0.0303
wR2 = 0.0716
R1 = 0.0254
wR2 = 0.0629 
R indices (all data) R1 = 0.0338wR2 = 0.0737
R1 = 0.0380
wR2 = 0.0749
R1 = 0.0278
wR2 = 0.0642 
Final ρmax,min (e– /Å3) 0.283 and -0.166 0.387 and -0.280 0.30/-0.69 
Flack parameter -0.02(3) -0.009(5) -0.018(10)
CSD number 1823199 1823200 1585759
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Supplementary Table 8: Crystallographic data of crystals containing ephedrinium iodide (form I), oxalate 
and thiocyanate salts. 
name [(+)-EphH][iodide], 
form I
[(+)-EphH]2[oxalate] [(+)-EphH] 
thiocyanate 
Empirical formula [C10H16NO]I [C10H16NO]2[C2O4] [C10H16NO]SCN 
Diffractometer Synergy SuperNova Synergy 
Wavelength (Å) 0.71073 0.71073 1.54184 
mol. weight (g/mol) 293.14 420.49 224.32 
Crystal system orthorhombic monoclinic orthorhombic 
Space group P212121 C2 P212121 
a (Å)  7.32726(12) 13.5545(2) 6.09862(6)  
b (Å) 18.9411(3) 5.84781(7) 7.52704(9)  
c (Å) 25.6662(5) 14.1657(2) 27.3811(3)  
α (°) 90 90 90 
β (°)  90 110.071(2) 90 
γ (°)  90 90 90 
Volume (Å3) 3562.12(11) 1054.64(3) 1256.92(2)  
Z 12 2 4 
Density(calc.) (g/cm3) 1.64 1.324 1.185  
Linear abs. coeff. (mm-1) 2.664 0.096 2.107 
F(000) 1728 452 480 
Crystal size (mm3) 0.29 × 0.17 × 0.05 0.39 × 0.18 × 0.11 0.16 × 0.14 × 0.010  
Crystal description plate, colorless prism, colorless colourless plate 
θ range (°) 2.150; 33.484 3.591; 35.243 3.228; 78.698 
Reflections collected 88148 20898 10879 
Indep. reflections 12569[Rint = 0.0322]
4451
[Rint = 0.0255]
2659  
[Rint = 0.0261] 
Reflections obs. 11728 4049 2582 
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I) I > 2.0σ(I) 
Completeness to θ (°) 0.999 to 25.242 0.996 to 25.242 99.6 % to 67.684°  
Absorption corr. gaussian gaussian multi-scan 
Min. and max. transm. 0.419 and 1 0.568 and 1 0.82868 and 1 
Reflections / restraints / 
parameters 12569 / 0 / 361 4451 / 1 / 145 2659 / 0 / 139 
Goodness-of-fit on F2 1.067 1.05 1.048 
Final R ind. [I > 2.0σ(I)] R1 = 0.0225 wR2 = 0.0472
R1 = 0.0337
wR2 = 0.0811
R1 = 0.0258 
wR2 = 0.0672 
R indices (all data) R1 = 0.0258  wR2 = 0.0480
R1 = 0.0418, 
wR2 = 0.0864
R1 = 0.0267 
wR2 = 0.0676 
Final ρmax,min (e– /Å3) 0.92 and -0.898 0.33 and -0.18 0.174 and -0.164 
Flack parameter -0.020(5) 0.2(2) -0.005(6) 
CSD number 1585758 1585760 1823201 
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Supplementary Table 9: Crystallographic data of crystals containing trazodone 
name [TrH][iodide] [TrH]2[oxalate] 
·10(H2O) 
[Tr]·2(H2O)
Empirical formula [C19H23ClN5O]I [C19H23ClN5O]2 
[C2O4]·10(H2O) 
C19H22ClN5O
·2(H2O)
Diffractometer SuperNova SuperNova SuperNova
Wavelength (Å) 0.71073 1.54184 1.54184
mol. weight (g/mol) 499.77 1013.92 405.88
Crystal system monoclinic monoclinic monoclinic
Space group P21/c I2/a P21/c
a (Å)  12.9279(2) 15.1489(4) 7.10113(10)
b (Å) 12.54570(15) 13.2904(4) 13.6250(2)
c (Å) 13.13900(15) 24.5940(8) 20.6821(3)
α (°) 90 90 90
β (°)  109.8430(12) 97.293(3) 91.5054(12)
γ (°)  90 90 90
Volume (Å3) 2004.48(5) 4911.6(3) 2000.36(5)
Z 4 4 4
Density(calc.) (g/cm3) 1.656 1.371 1.354
Linear abs. coeff. (mm-1) 1.75 1.85 1.948
F(000) 1000 2152 856
Crystal size (mm3) 0.20 × 0.07 × 0.04 0.14 × 0.07 × 0.04 0.28 × 0.15 × 0.02
Crystal description plate, colorless needle, colorless plate, colorless
θ range (°) 3.248; 33.727 3.624; 76.973 3.886; 74.266
Reflections collected 27961 20149 29860
Indep. reflections 7970 [Rint = 0.0340] 5113 [Rint = 0.0336] 4036 [Rint = 0.0332]
Reflections obs. 6177 4562 3588
Criterion for obs. I > 2.0σ(I) I > 2.0σ(I)  I > 2.0σ(I) 
Completeness to θ (°) 0.995 to 25.242 1.000 to 67.684 1.000 to 67.684
Absorption corr. multi-scan gaussian multi-scan
Min. and max. transm. 0.649 and 1 0.783 and 1 0.733 and 1
Reflections / restraints / 
parameters 7970 / 0 / 244 5113 / 6 / 341 4036 / 10 / 337
Goodness-of-fit on F2 1.025 1.069 1.032
Final R ind. [I > 2.0σ(I)] 
R1 = 0.0336
wR2 = 0.0626
R1 = 0.0445 
wR2 = 0.1210 
R1 = 0.0408
wR2 = 0.1095
R indices (all data) 
R1 = 0.0527
wR2 = 0.0684
R1 = 0.0485 
wR2 = 0.1251 
R1 = 0.0456
wR2 = 0.1143
Final ρmax,min (e– /Å3) 0.71 and -0.45 0.24 and -0.32 0.37 and -0.26
CSD number 1585764 1585765 1585763
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